Acute Lymphoblastic Leukemia News and Research

RSS

Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells, the cells in the body that normally fight infections. There are two main types of white blood cells-lymphoid cells and myeloid cells. ALL affects lymphoid cells.

Giving children access to drug clinical trials is crucial, clofarabine approval shows

The accelerated approval of the drug clofarabine to treat relapsed or refractory pediatric acute lymphoblastic leukemia (ALL) demonstrates the importance of offering children rapid access to new treatments through clinical trials, according to investigators at St. Jude Children's Research Hospital. Refractory or relapsed ALL is a disease that resists treatment.

2 May 2005

New prognostic markers help identify risk of relapse

A recently completed clinical study has found new prognostic markers that may help clinicians identify those children with leukaemia who are at high risk of relapse and are most in need of intensified treatment to improve their chance of survival.

1 May 2005

Pattern of gene expression predicts multiple drug resistance, treatment failure in pediatric leukemia

The discovery of a specific pattern of gene expression linked to multiple-drug resistance of leukemic cells is giving researchers crucial information into why standard therapies fail to cure some children with acute lymphoblastic leukemia (ALL). This finding, from investigators at St. Jude Children’s Research Hospital, could lead to development of drugs that would overcome that resistance.

24 Apr 2005

Day care in infancy protects against childhood leukaemia

Children who attend day care centres on a regular basis in the first few months of life are less likely to develop leukaemia than children who do not, finds a study published online by the BMJ.

22 Apr 2005

Gene expression pattern predicts multiple drug resistance

St. Jude Children's Research Hospital discovery of genetic links to multi-drug resistance gives clinicians new insight into the cause of treatment failure and suggests targets for novel anti-leukemic drugs

19 Apr 2005

Genes TEL2 and MYC cooperate with each other to promote pediatric cases of the immune system cancer B-cell lymphoma

The genes TEL2 and MYC cooperate with each other to promote pediatric cases of the immune system cancer B-cell lymphoma. This finding, from investigators at St. Jude Children's Research Hospital, is published in the current issue of Molecular Cell Biology (MCB).

22 Mar 2005

Inherited traits and tumor mutations affect response to treatment of leukemia

The outcome of chemotherapy treatment for acute lymphoblastic leukemia (ALL) depends not only on the acquired genetic make-up of the leukemic cells, but on genes that children inherit from their parents. This study, from investigators at St. Jude Children's Research Hospital, is published in the online edition of Blood.

3 Mar 2005

Level of immune cell DNA in the blood might help predict success of stem cell transplantation

Measuring the quantity of a certain type of immune cell DNA in the blood could help physicians predict whether a bone marrow stem cell transplant will successfully restore a population of infection-fighting cells called T lymphocytes in a child.

7 Feb 2005

FDA knocks back anticancer drug Marqibo

Inex Pharmaceuticals announced today that United States Food and Drug Administration (FDA) provided an action letter detailing that the anticancer drug Marqibo (vincristine sulfate liposomes injection) is "not approvable" under the FDA's accelerated approval regulations based on the phase 2 clinical trial data submitted.

19 Jan 2005

First new leukemia treatment approved specifically for children in more than a decade

Ash Stevens was approved to manufacture the bulk drug substance Clofarabine, the active ingredient in Genzyme Corp.'s Clolar (clofarabine) for the treatment of children with refractory or relapsed Acute Lymphoblastic Leukemia (ALL). This is the first new leukemia treatment approved specifically for children in more than a decade.

4 Jan 2005

Chemotherapy lowers levels of antioxidants and micronutrients

Children undergoing chemotherapy for acute lymphoblastic leukemia (ALL) have significant changes in their antioxidant and micronutrient status which are related to their treatment outcomes, according to the results of a novel prospective study.

28 Dec 2004

Researchers step closer to cure for common childhood cancer

Acute lymphoblastic leukemia (ALL) is a malignant disease caused by the abnormal growth and development of white blood cells (WBC) in the bone marrow and blood. ALL is the most common cancer occurring in children with an annual rate of approximately 30 to 40 new cases per million.

5 Dec 2004

Genetic target found for pediatric leukemia

A molecular target newly discovered by scientists at two prestigious research institutes may pave the way for new treatments that could combat an aggressive form of leukemia, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Methylphenidate improves attention, behavior of children surviving acute lymphoblastic leukemia, brain tumors

Children who suffer from behavioral and learning problems after their central nervous systems have been exposed to chemotherapy or radiation appear to benefit from treatment with methylphenidate (MPH), the drug commonly known by the brand name Ritalin®.

4 Dec 2004

Improved risk classification for patients with acute lymphoblastic leukemia offers hope for eliminating irradiation

Improved risk classification for patients with acute lymphoblastic leukemia (ALL), coupled with more intensive intrathecal chemotherapy for high risk patients and the use of a drug called dexamethasone, could one day permit physicians to omit irradiation as a part of routine treatment.

1 Nov 2004

Babies who are breastfed have a lower risk of developing childhood leukemia

The paper, to be published November in the journal Public Health Reports, found that breastfeeding was linked to lower risks of both acute lymphoblastic leukemia (ALL), the most common of the childhood cancers, and acute myeloblastic leukemia (AML).

28 Oct 2004

New treatment for T-cell acute lymphoblastic leukaemia

IL-7, a hormone-like protein involved in cell-cell interaction, has been associated with increased survival and expansion of T-cell acute lymphoblastic leukaemia (T-ALL).

9 Sep 2004

Protein sources, such as beef and beans beneficial in lowering childhood leukemia risk

A new study suggests that eating more vegetables, fruit and protein before pregnancy may lower the risk of having a child who develops leukemia, the most common childhood cancer in the United States.

8 Sep 2004

Chemotherapy experts refute ASCO recommendations on use of drug sensitivity and resistance assays

A group of leading chemotherapy experts assembled as the Clinical Oncologists for Individualized Therapy (COFIT) refute the findings of the American Society of Clinical Oncology (ASCO) technology assessment panel regarding the use of chemotherapy sensitivity and resistance assays (CSRAs).

1 Sep 2004

Fruit and vegetables eaten before pregnancy lowers risk of leukemia

A new study led by researchers at the University of California, Berkeley, suggests that women who eat more vegetables, fruit and foods containing protein before pregnancy may have a lower risk of having a child who develops leukemia, the most common childhood cancer in the United States.

20 Aug 2004